S&P 500   3,344.91 (-0.20%)
DOW   27,499.82 (-0.31%)
QQQ   277.19 (+0.00%)
AAPL   114.50 (-0.40%)
MSFT   208.83 (-0.29%)
FB   259.31 (+0.97%)
GOOGL   1,465.49 (+0.47%)
AMZN   3,170.00 (-0.13%)
TSLA   416.61 (-1.09%)
NVDA   525.07 (+0.70%)
BABA   278.75 (+0.99%)
CGC   14.42 (+1.48%)
MU   50.87 (+2.31%)
GE   6.15 (-0.81%)
AMD   81.00 (+1.91%)
T   28.40 (+0.07%)
F   6.66 (-0.45%)
ACB   4.63 (-3.14%)
GILD   62.48 (-0.59%)
NFLX   489.70 (-0.19%)
DIS   124.71 (-1.02%)
BA   163.44 (-1.59%)
BAC   23.95 (-0.58%)
S&P 500   3,344.91 (-0.20%)
DOW   27,499.82 (-0.31%)
QQQ   277.19 (+0.00%)
AAPL   114.50 (-0.40%)
MSFT   208.83 (-0.29%)
FB   259.31 (+0.97%)
GOOGL   1,465.49 (+0.47%)
AMZN   3,170.00 (-0.13%)
TSLA   416.61 (-1.09%)
NVDA   525.07 (+0.70%)
BABA   278.75 (+0.99%)
CGC   14.42 (+1.48%)
MU   50.87 (+2.31%)
GE   6.15 (-0.81%)
AMD   81.00 (+1.91%)
T   28.40 (+0.07%)
F   6.66 (-0.45%)
ACB   4.63 (-3.14%)
GILD   62.48 (-0.59%)
NFLX   489.70 (-0.19%)
DIS   124.71 (-1.02%)
BA   163.44 (-1.59%)
BAC   23.95 (-0.58%)
S&P 500   3,344.91 (-0.20%)
DOW   27,499.82 (-0.31%)
QQQ   277.19 (+0.00%)
AAPL   114.50 (-0.40%)
MSFT   208.83 (-0.29%)
FB   259.31 (+0.97%)
GOOGL   1,465.49 (+0.47%)
AMZN   3,170.00 (-0.13%)
TSLA   416.61 (-1.09%)
NVDA   525.07 (+0.70%)
BABA   278.75 (+0.99%)
CGC   14.42 (+1.48%)
MU   50.87 (+2.31%)
GE   6.15 (-0.81%)
AMD   81.00 (+1.91%)
T   28.40 (+0.07%)
F   6.66 (-0.45%)
ACB   4.63 (-3.14%)
GILD   62.48 (-0.59%)
NFLX   489.70 (-0.19%)
DIS   124.71 (-1.02%)
BA   163.44 (-1.59%)
BAC   23.95 (-0.58%)
S&P 500   3,344.91 (-0.20%)
DOW   27,499.82 (-0.31%)
QQQ   277.19 (+0.00%)
AAPL   114.50 (-0.40%)
MSFT   208.83 (-0.29%)
FB   259.31 (+0.97%)
GOOGL   1,465.49 (+0.47%)
AMZN   3,170.00 (-0.13%)
TSLA   416.61 (-1.09%)
NVDA   525.07 (+0.70%)
BABA   278.75 (+0.99%)
CGC   14.42 (+1.48%)
MU   50.87 (+2.31%)
GE   6.15 (-0.81%)
AMD   81.00 (+1.91%)
T   28.40 (+0.07%)
F   6.66 (-0.45%)
ACB   4.63 (-3.14%)
GILD   62.48 (-0.59%)
NFLX   489.70 (-0.19%)
DIS   124.71 (-1.02%)
BA   163.44 (-1.59%)
BAC   23.95 (-0.58%)
Log in
NASDAQ:SUPN

Supernus Pharmaceuticals Stock Forecast, Price & News

$20.50
-0.28 (-1.35 %)
(As of 09/29/2020 10:18 AM ET)
Add
Compare
Today's Range
$20.50
Now: $20.50
$20.71
50-Day Range
$20.20
MA: $22.11
$25.05
52-Week Range
$13.12
Now: $20.50
$29.36
Volume630 shs
Average Volume542,851 shs
Market Capitalization$1.08 billion
P/E Ratio9.28
Dividend YieldN/A
Beta1.46
Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine. The company's product candidates comprise SPN-812, a viloxazine hydrochloride, which is in Phase III clinical trial that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with ADHD; SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression; SPN-604 extended release oxcarbazepine for bipolar; and SPN-817 that is in phase I clinical trial for treating epilepsy. The company markets its products through wholesalers and distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.
Read More
Supernus Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.1Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.80 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:SUPN
CUSIP86845910
Phone301-838-2500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$392.76 million
Cash Flow$2.41 per share
Book Value$11.35 per share

Profitability

Net Income$113.06 million

Miscellaneous

Employees448
Market Cap$1.08 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$20.50
-0.28 (-1.35 %)
(As of 09/29/2020 10:18 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SUPN News and Ratings via Email

Sign-up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Supernus Pharmaceuticals (NASDAQ:SUPN) Frequently Asked Questions

How has Supernus Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Supernus Pharmaceuticals' stock was trading at $16.15 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SUPN stock has increased by 27.1% and is now trading at $20.53.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Supernus Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Supernus Pharmaceuticals
.

When is Supernus Pharmaceuticals' next earnings date?

Supernus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Supernus Pharmaceuticals
.

How were Supernus Pharmaceuticals' earnings last quarter?

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) released its quarterly earnings results on Tuesday, August, 18th. The specialty pharmaceutical company reported $0.65 EPS for the quarter, topping analysts' consensus estimates of $0.42 by $0.23. The specialty pharmaceutical company earned $126.73 million during the quarter, compared to analyst estimates of $126.70 million. Supernus Pharmaceuticals had a return on equity of 19.44% and a net margin of 27.85%.
View Supernus Pharmaceuticals' earnings history
.

What guidance has Supernus Pharmaceuticals issued on next quarter's earnings?

Supernus Pharmaceuticals updated its second quarter 2020 After-Hours earnings guidance on Tuesday, August, 11th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $126.7-126.7 million, compared to the consensus revenue estimate of $89.34 million.

What price target have analysts set for SUPN?

4 equities research analysts have issued twelve-month price objectives for Supernus Pharmaceuticals' shares. Their forecasts range from $24.00 to $31.00. On average, they anticipate Supernus Pharmaceuticals' stock price to reach $26.33 in the next year. This suggests a possible upside of 28.3% from the stock's current price.
View analysts' price targets for Supernus Pharmaceuticals
.

Are investors shorting Supernus Pharmaceuticals?

Supernus Pharmaceuticals saw a increase in short interest during the month of August. As of August 14th, there was short interest totaling 5,380,000 shares, an increase of 12.1% from the July 30th total of 4,800,000 shares. Based on an average daily volume of 491,600 shares, the days-to-cover ratio is currently 10.9 days. Currently, 10.7% of the company's shares are sold short.
View Supernus Pharmaceuticals' Short Interest
.

Who are some of Supernus Pharmaceuticals' key competitors?

What other stocks do shareholders of Supernus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Supernus Pharmaceuticals investors own include NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), GW Pharmaceuticals PLC- (GWPH), Netflix (NFLX), Corcept Therapeutics (CORT) and Cara Therapeutics (CARA).

Who are Supernus Pharmaceuticals' key executives?

Supernus Pharmaceuticals' management team includes the following people:
  • Mr. Jack A. Khattar, Founder, Pres, CEO, Sec. & Director (Age 58)
  • Mr. Gregory S. Patrick, Sr. VP & CFO (Age 68)
  • Dr. Padmanabh P. Bhatt, Chief Scientific Officer & Sr. VP of Intellectual Property (Age 62)
  • Dr. Stefan K. F. Schwabe, Chief Medical Officer and Exec. VP of R&D (Age 67)
  • Dr. Todd Horich M.B.A., Ph.D., VP of Marketing

What is Supernus Pharmaceuticals' stock symbol?

Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."

How do I buy shares of Supernus Pharmaceuticals?

Shares of SUPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Supernus Pharmaceuticals' stock price today?

One share of SUPN stock can currently be purchased for approximately $20.53.

How big of a company is Supernus Pharmaceuticals?

Supernus Pharmaceuticals has a market capitalization of $1.08 billion and generates $392.76 million in revenue each year. The specialty pharmaceutical company earns $113.06 million in net income (profit) each year or $2.10 on an earnings per share basis. Supernus Pharmaceuticals employs 448 workers across the globe.

What is Supernus Pharmaceuticals' official website?

The official website for Supernus Pharmaceuticals is www.supernus.com.

How can I contact Supernus Pharmaceuticals?

Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The specialty pharmaceutical company can be reached via phone at 301-838-2500 or via email at [email protected]

This page was last updated on 9/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.